Neuroendocrine prostate cancer

Prostate Cancer: A Comprehensive Perspective

Volumn , Issue , 2013, Pages 277-282

  Beltran, Himisha ^a   Mosquera, Juan Miguel ^a   Rubin, Mark A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84900413036     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4471-2864-9_22     Document Type: Chapter

References (28)

1. Sun S, Sprenger CC, Vessella RL, et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest. 2010;120:2715-30.
2. Nakada SY, di Sant'Agnese PA, Moynes RA, et al. The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissue. Cancer Res. 1993;53:1967-70.
3. Abrahamsson PA, di Sant'Agnese PA. Neuroendocrine cells in the human prostate gland. J Androl. 1993;14:307-9.
4. Abrahamsson PA. Neuroendocrine cells in tumour growth of the prostate. Endocr Relat Cancer. 1999;6:503-19.
5. di Sant'Agnese PA. Neuroendocrine differentiation in human prostatic carcinoma. Hum Pathol. 1992;23:287-96.
6. Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma. Prostate. 1999;39:135-48.
7. Mucci NR, Akdas G, Manely S, Rubin MA. Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression. Hum Pathol. 2000;31:406-14.
8. Weinstein MH, Partin AW, Veltri RW, Epstein JI. Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. Hum Pathol. 1996;27:683-7.
9. Berruti A, Bollito E, Cracco CM, et al. The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen-deprivation therapy. Prostate. 2010;70:718-26.
10. Berruti A, Mosca A, Tucci M, et al. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocr Relat Cancer. 2005;12:109-17.
11. Berruti A, Dogliotti L, Mosca A, et al. Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer. 2000;88:2590-7.
12. Yuan TC, Veeramani S, Lin MF. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr Relat Cancer. 2007;14:531-47.
13. Huang J, Yao JL, di Sant'Agnese PA, Yang Q, Bourne PA, Na Y. Immunohistochemical characterization of neuroendocrine cells in prostate cancer. Prostate. 2006;66:1399-406.
14. Lotan TL, Gupta NS, Wang W, et al. ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol. 2011; 24:820-8.
15. Vashchenko N, Abrahamsson PA. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol. 2005;47:147-55.
16. Yang JC, Ok JH, Busby JE, Borowsky AD, Kung HJ, Evans CP. Aberrant activation of androgen receptor in a new neuropeptideautocrine model of androgen-insensitive prostate cancer. Cancer Res. 2009;69:151-60.
17. Scheble VJ, Braun M, Wilbertz T, et al. ERG rearrangement in small cell prostatic and lung cancer. Histopathology. 2010;56:937-43.
18. Scheble VJ, Braun M, Beroukhim R, et al. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol. 2010;23:1061-7.
19. Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson Jr HF. Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate. Cancer. 1997;80:2109-19.
20. May M, Siegsmund M, Hammermann F, Loy V, Gunia S. Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy. Scand J Urol Nephrol. 2007;41:375-81.
21. Rojas-Corona RR, Chen LZ, Mahadevia PS. Prostatic carcinoma with endocrine features. A report of a neoplasm containing multiple immunoreactive hormonal substances. Am J Clin Pathol. 1987;88: 759-62.
22. Hirano D, Okada Y, Minei S, Takimoto Y, Nemoto N. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol. 2004;45:586-92; discussion 92.
23. Cussenot O, Villette JM, Valeri A, et al. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. J Urol. 1996;155:1340-3.
24. Flechon A, Pouessel D, Ferlay C, et al. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial. Ann Oncol. 2011. doi: 10.1093/ annonc/mdr004 .
25. Papandreou CN, Daliani DD, Thall PF, et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol. 2002;20:3072-80.
26. Angelsen A, Syversen U, Stridsberg M, Haugen OA, Mjolnerod OK, Waldum HL. Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate. Prostate. 1997;31:110-7.
27. Andrew SG, Jiaoti H, Changyong G, Isla PG, Owen NW. Identifi-cation of a cell of origin for human prostate cancer. Science. 2010; 329(5991):568-571.
28. Himisha B, David SR, Kyung P, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discovery. 2011;1:487-495.